Interleukin-3: Its biology and potential uses in pediatric hematology/oncology

M. C. Sunderland, G. David Roodman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The hematopoietic growth factor interleukin (IL)-3 is a potent regulator of blood cell proliferation. It promotes the survival, proliferation, and development of hematopoietic stem cells and committed progenitor cells of the granulocyte-macrophage, erythrocyte, eosinophil, basophil, megakaryocyte, mast cell, and lymphocyte lineages. In addition, IL-3 enhances mature myeloid cell functions such as phagocytosis and activation of basophils and eosinophils, as well as monocyte cytotoxicity. The first phase of clinical trials suggested that IL-3 may augment myelopoiesis in a number of clinical conditions. It may be efficacious for treatment of primary marrow disorders, including myelodysplastic syndromes and aplastic anemia. However, replacement therapy with IL-3 alone is probably not sufficient to obtain maximal stimulation of myelopoiesis. Preclinical and clinical studies published to date suggest that sequential use or combinations of growth factors will be needed to obtain optimal hematopoietic responses.

Original languageEnglish (US)
Pages (from-to)414-425
Number of pages12
JournalJournal of Pediatric Hematology/Oncology
Volume13
Issue number4
StatePublished - 1991
Externally publishedYes

Fingerprint

Interleukin-3
Hematology
Myelopoiesis
Pediatrics
Basophils
Eosinophils
Intercellular Signaling Peptides and Proteins
Granulocyte-Macrophage Progenitor Cells
Megakaryocytes
Aplastic Anemia
Myelodysplastic Syndromes
Cell Lineage
Myeloid Cells
Hematopoietic Stem Cells
Phagocytosis
Mast Cells
Monocytes
Blood Cells
Erythrocytes
Bone Marrow

Keywords

  • Hematopoietic stem cells
  • Interleukin-3
  • Marrow disorders

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Interleukin-3 : Its biology and potential uses in pediatric hematology/oncology. / Sunderland, M. C.; Roodman, G. David.

In: Journal of Pediatric Hematology/Oncology, Vol. 13, No. 4, 1991, p. 414-425.

Research output: Contribution to journalArticle

@article{99626bff27e649b98b374e851178f307,
title = "Interleukin-3: Its biology and potential uses in pediatric hematology/oncology",
abstract = "The hematopoietic growth factor interleukin (IL)-3 is a potent regulator of blood cell proliferation. It promotes the survival, proliferation, and development of hematopoietic stem cells and committed progenitor cells of the granulocyte-macrophage, erythrocyte, eosinophil, basophil, megakaryocyte, mast cell, and lymphocyte lineages. In addition, IL-3 enhances mature myeloid cell functions such as phagocytosis and activation of basophils and eosinophils, as well as monocyte cytotoxicity. The first phase of clinical trials suggested that IL-3 may augment myelopoiesis in a number of clinical conditions. It may be efficacious for treatment of primary marrow disorders, including myelodysplastic syndromes and aplastic anemia. However, replacement therapy with IL-3 alone is probably not sufficient to obtain maximal stimulation of myelopoiesis. Preclinical and clinical studies published to date suggest that sequential use or combinations of growth factors will be needed to obtain optimal hematopoietic responses.",
keywords = "Hematopoietic stem cells, Interleukin-3, Marrow disorders",
author = "Sunderland, {M. C.} and Roodman, {G. David}",
year = "1991",
language = "English (US)",
volume = "13",
pages = "414--425",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Interleukin-3

T2 - Its biology and potential uses in pediatric hematology/oncology

AU - Sunderland, M. C.

AU - Roodman, G. David

PY - 1991

Y1 - 1991

N2 - The hematopoietic growth factor interleukin (IL)-3 is a potent regulator of blood cell proliferation. It promotes the survival, proliferation, and development of hematopoietic stem cells and committed progenitor cells of the granulocyte-macrophage, erythrocyte, eosinophil, basophil, megakaryocyte, mast cell, and lymphocyte lineages. In addition, IL-3 enhances mature myeloid cell functions such as phagocytosis and activation of basophils and eosinophils, as well as monocyte cytotoxicity. The first phase of clinical trials suggested that IL-3 may augment myelopoiesis in a number of clinical conditions. It may be efficacious for treatment of primary marrow disorders, including myelodysplastic syndromes and aplastic anemia. However, replacement therapy with IL-3 alone is probably not sufficient to obtain maximal stimulation of myelopoiesis. Preclinical and clinical studies published to date suggest that sequential use or combinations of growth factors will be needed to obtain optimal hematopoietic responses.

AB - The hematopoietic growth factor interleukin (IL)-3 is a potent regulator of blood cell proliferation. It promotes the survival, proliferation, and development of hematopoietic stem cells and committed progenitor cells of the granulocyte-macrophage, erythrocyte, eosinophil, basophil, megakaryocyte, mast cell, and lymphocyte lineages. In addition, IL-3 enhances mature myeloid cell functions such as phagocytosis and activation of basophils and eosinophils, as well as monocyte cytotoxicity. The first phase of clinical trials suggested that IL-3 may augment myelopoiesis in a number of clinical conditions. It may be efficacious for treatment of primary marrow disorders, including myelodysplastic syndromes and aplastic anemia. However, replacement therapy with IL-3 alone is probably not sufficient to obtain maximal stimulation of myelopoiesis. Preclinical and clinical studies published to date suggest that sequential use or combinations of growth factors will be needed to obtain optimal hematopoietic responses.

KW - Hematopoietic stem cells

KW - Interleukin-3

KW - Marrow disorders

UR - http://www.scopus.com/inward/record.url?scp=0025833871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025833871&partnerID=8YFLogxK

M3 - Article

C2 - 1785668

AN - SCOPUS:0025833871

VL - 13

SP - 414

EP - 425

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -